ARS Pharmaceuticals, Inc. SPRY Net unrealized gains (losses) on securities still held
Net unrealized gains (losses) on securities still held at other companies
Other financials
Where this comes from
Reported directly by ARS Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax.
The official record: ARS Pharmaceuticals, Inc.’s 10-Q, filed May 15, 2026, on SEC EDGAR. View the filing →
Ask your AI about ARS Pharmaceuticals, Inc.'s net unrealized gains (losses) on securities still held.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is ARS Pharmaceuticals, Inc.'s net unrealized gains (losses) on securities still held?
- ARS Pharmaceuticals, Inc. (SPRY) reported net unrealized gains (losses) on securities still held of -$221K in Q1 2026.
- How has ARS Pharmaceuticals, Inc.'s net unrealized gains (losses) on securities still held changed year-over-year?
- ARS Pharmaceuticals, Inc.'s net unrealized gains (losses) on securities still held decreased by 49.3% year-over-year, from -$148K to -$221K.
- What does net unrealized gains (losses) on securities still held mean?
- This reflects the change in value of investment securities held by the company that have not yet been sold. It represents unrealized gains or losses that are excluded from net income but impact the company's total equity. This metric is essential for assessing the volatility and market risk associated with the company's investment portfolio.